Abstract. Geniposide, as a type of iridoid glycoside, has antioxidative capacity. However, the mechanism underlying the effect of geniposide in cadmium (Cd)-induced osteoblast injury remains only partly elucidated. In the present study, Cell Counting Kit-8 (CCK-8) was used to determine MC-3T3-E1 cell viability. Flow cytometry was used to determine the rate of apoptosis and levels of reactive oxygen species (ROS). Oxidative stress-related factors were assessed using enzyme-linked immunosorbent method (ELISA). Quantitative real-time polymerase chain reaction (qPCR) and western blotting were used to evaluate apoptosis- and bone formation-related genes and nuclear factor erythroid 2-related factor (Nrf2) signaling. It was demonstrated that geniposide increased the viability of the Cd-treated MC-3T3-E1 cells. Geniposide decreased apoptosis and ROS accumulation compared to these parameters in the Cd group. Geniposide attenuated oxidative stress-related factors, malondialdehyde and lactate dehydrogenase and increased antioxidant key enzyme superoxide dismutase (SOD). The expression levels of Bax, Bcl-2 and survivin were modulated by geniposide. Additionally, the mRNA and protein expression of the receptor activator of NF-κB ligand (RANKL) and osteonectin were significantly increased, while osteoprotegerin was decreased by geniposide treatment compared to the Cd groups. Geniposide also enhanced Nrf2, heme oxygenase-1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1) expression. The present study identified a potential agent for the treatment of Cd-induced osteoblast injury.

Introduction

Cadmium, an environmental pollutant, seriously affects public health worldwide. A large number of studies have shown that cadmium exerts multi-organ and multi-system toxicity, and that it is able to produce carcinogenic, orthodontic and mutagenic effects, for example, muscle wastage, hemolysis, immunosuppression, and a decrease in fertility (1-4). ‘Itai-itai’ disease was first known to the world after mining-related cadmium poisoning in Japan in 1955 (5,6). Bone is a main target organ for cadmium toxicity. Previous studies have indicated that cadmium may damage osteoblasts in culture by decreasing bone calcium and prostaglandin 2 (PGE2) levels (7-9). It has also been confirmed that cadmium affects bone metabolism both directly and indirectly (10). Researchers also demonstrated that the osteotoxicity of cadmium may be caused by alterations to vitamin D metabolism and disruption of the balance of calcium absorption and excretion (11,12). Moreover, cadmium damage directly increases the risk of bone fracture and osteoporosis, and cadmium can affect the activation of osteoclasts and osteoblasts, leading to imbalance between bone resorption and formation (13-18).

Under normal circumstances, the body or cells constantly produce free radicals, while the antioxidant system scavenges these free radicals. Such a dynamic balance maintains a stable metabolism in contrast to the condition in which an imbalance would cause free radical accumulation and lipid peroxidation (19). Cadmium not only induces the initiation of oxidative damage, produces lipid peroxide, destroys the intracellular state of redox equilibrium, but also interferes with the function of the antioxidant system. Cadmium mainly mediates oxidative stress through an indirect reaction pathway, largely by reducing the level of antioxidants in cells and mediating mitochondrial functional damage, increasing the production of reactive oxygen species (ROS) (20-23). Therefore, the toxic effects of cadmium on osteoblasts may be the result of oxidative stress and ROS levels.

Geniposide, a type of iridoid glycoside, is the main active component of Gardenia jasminoides (Rubiaceae). Geniposide is considered to have anti-inflammatory, antioxidant activity as well as antitumor properties (24-28). Researchers have reported that geniposide also exhibits effects on brain by reducing inflammatory response of microglial cells and protecting the neural tissue from cerebral ischemia (29,30); and on digestive system diseases, namely by suppressing helicobacter pylori infections (31). Geniposide activates osteoblasts to facilitate osteogenesis, and suppresses osteoclast activity and inhibits bone resorption (32). In addition, geniposide may promote the growth of osteoblast MC3T3-E1 cells, and suppress...
H$_2$O$_2$-induced apoptosis (33). To the best of our knowledge, current investigations have focused heavily on the antioxidative capacity of geniposide. Recent studies have shown that geniposide protected PC12 cells from oxidative damage through its radical scavenging activity (34,35). Geniposide was also found to protect against oxygen and glucose deprivation-induced neuronal cell death in rat hippocampal slice cultures (36). Thus, it was speculated that geniposide may protect osteoblasts from oxidative stress induced by cadmium.

The present study aimed to determine the protective effects of geniposide against cadmium-induced osteoblast (MC-3T3-E1) injury, and to investigate its underlying protective mechanisms with a focus on oxidative stress.

Materials and methods

Reagents. Geniposide (purity >98%) was purchased from Pure-one Bio Technology, Co., Ltd (Shanghai, China). Geniposide was dissolved in water, pH 7.4. Cadmium chloride (CdCl$_2$) was purchased from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany).

Cell culture and morphological observation. Rat MC-3T3-E1 cells (Riken Cell Bank, Tsukuba, Ibaraki, Japan) were cultured in Dulbecco's modified Eagle's medium (DMEM; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% (v/v) fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and 100 U/ml penicillin (or 100 µg/ml streptomycin) in a 37°C incubator with 5% CO$_2$ humidified atmosphere. The morphology of primary cultured MC-3T3-E1 cells was observed using an inverted microscope (x40).

Cell Counting Kit-8 (CCK-8) assay. The CCK-8 assay kit (Beyotime Institute of Biotechnology, Haimen, China) was used to measure cell viability. MC-3T3-E1 cells (5x10$^3$ cells/well) were cultured in 96-well plates and were treated with CdCl$_2$ (0-20 µM). Geniposide (100, 200 and 400 µg/ml) was used as previously described (37) to treat the cells in order to detect its effect on CdCl$_2$-induced injury.

For the cell viability assay, 10 µl CCK-8 solution was added into each well, and the cells were incubated for another 3 h at 37°C. Cell viability was determined using a microplate reader as previously described (38) by reading the optical density at a wavelength of 450 nm, and at a reference wavelength of 630 nm.

Flow cytometry. Cell apoptosis was detected in MC-3T3-E1 cell cultures using a flow cytometer. The cells were harvested and re-suspended in Annexin binding buffer at 1x10$^5$ cells/ml. Then, the suspension was incubated with Annexin V-FITC and propidium iodide (PI) [cat. no. 70-AP101-60; MultiSciences (Lianke) Biotech Co., Ltd., Hangzhou, China] in the dark for 15 min at 4°C. The apoptosis of the cell samples was analyzed by flow cytometry with BD CellQuest Pro Software version 1.2 (BD Biosciences, San Jose, CA, USA).

The ROS levels were measured using 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) as previously described (39). DCFH-DA (Sigma-Aldrich; Merck KGaA), without fluorescence, can enter the cell membrane and form DCFH in the cell. DCFH is then oxidized to form a fluorescent substance DCF in the presence of ROS. MC-3T3-E1 cells were stained with DCFDA and held for 30 min at room temperature. Finally, DCF fluorescence levels were measured by flow cytometry and the data were analyzed using Summit Software (version 4.3; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA).

Enzyme-linked immunoassorbent assay (ELISA). Oxidative stress-related factors malondialdehyde (MDA; cat. no. ml077384; Enzyme-linked Biotechnology Co., Ltd., Shanghai, China), lactate dehydrogenase (LDH; cat. no. ml076593; Enzyme-linked Biotechnology Co., Ltd.) and superoxide dismutase (SOD; cat. no. ml077379; Enzyme-linked Biotechnology Co., Ltd.) were measured using ELISA. MC-3T3-E1 cells were seeded on a 24-well plate, and cell-free supernatants were harvested after 3 h. The concentrations of MDA, LDH and SOD in the supernatants of MC-3T3-E1 cells were determined using ELISA kits following the manufacturer's instructions.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). RT-qPCR was performed for the purpose of examining gene expression profiles of Bax, Bcl-2, survivin, NF-xB ligand (RANKL), osteoprotegerin (OPG), osterix, nuclear factor erythroid 2-related factor (Nrf2), heme oxygenase-1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1). Total RNA was extracted using TRIzol® regent (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's instructions. RNA was reverse transcribed into cDNA using GoScript™ RT kit (Promega Corporation, Madison, WI, USA). The RT temperature protocol consisted of 37°C for 15 min and at 85°C for 5 sec. RT-qPCR was conducted using SYBR Fast qPCR Mix (Invitrogen; Thermo Fisher Scientific, Inc.) The thermocycling conditions were: 94°C for 3 min for an initial denaturation, followed by 30 denaturation cycles at 94°C for 5 sec, annealing and elongation at 60°C for 30 sec; and final extension at 72°C for 10 min. The primer sequences are summarized in Table I. The quantity of RNA was calculated using the 2$^{ΔΔCt}$ method (40), and the level of expression of an RNA was normalized to GAPDH (denoted ‘relative expression’).

Western blot analysis. MC-3T3-E1 cells were washed three times with PBS, and detached from the dishes by scraping. Cells were centrifuged at 12,000 x g for 5 min at 4°C and re-suspended in RIPA lysis buffer (Thermo Fisher Scientific, Inc.) with phenylmethanesulfonyl fluoride (PMSF) at 1:200 dilution. The homogenate was centrifuged at 12,000 x g for 10 min at 4°C. Protein concentrations were quantified using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology). Equivalent amounts of total protein (20 µg/lane) were loaded on a 10% Tris-glycine, 10% SDS-PAGE (Beyotime Institute of Biotechnology) for separation. Proteins were then transferred onto a polyvinylidene difluoride membrane, which were blocked with 5% milk in TBS containing 0.2% Tween-20 (TBST) at room temperature for 2 h, and incubated with primary antibodies as follows: Rabbit anti-Bcl-2 (cat. no. ab32124, 1:1,000) anti-bax (cat. no. ab32503, 1:1,000); anti-survivin (cat. no. ab276424, 1:1,000); rabbit anti-RANKL (cat. no. ab9957, 1:1,000), anti-OPG (cat. no. 8D5: role of Geniposide in Cadmium-induced Osteoblast Injury.
Table I. Primer sequences.

| Gene    | Primer sequence (5’-3’) |
|---------|-------------------------|
| Bax     | Forward: TTCACTCCAGATCGAGCAGAG  
Reverse: TGAAGACTCCAGCCAAAGAT |
| Bcl-2   | Forward: CTTTGGACACACATGCCTG  
Reverse: GGTTCGCGGCTCTCATTTG |
| Survivin | Forward: CACTTGTCCCTTGCTGTCA  
Reverse: ATGGTGTTGGAAGAGCCAGTA |
| RANKL   | Forward: CCGAGCTCGTCGTCGCTTGT  
Reverse: ATGGTGTTGGAAGAGCCAGTA |
| OPG     | Forward: GCACGATCGTCGTCGCTTGT  
Reverse: ATGGTGTTGGAAGAGCCAGTA |
| Nrf2    | Forward: GCCAAGCTAAGACTGACAGAC  
Reverse: GATTCGTTCAGCAGCAGCA |
| HO-1    | Forward: TTGCTCTTGCGATTGAGG  
Reverse: CTCTACCGACATCTG |
| NQO1    | Forward: CATTCTGAAGAGCTGTTTGA  
Reverse: CTAGCTTTGATCTGTTGTCAG |
| GAPDH   | Forward: GCCACAGTCAGGCGTGGACAGA  
Reverse: ATGGTGTTGGAAGAGCCAGTA |

no. ab73400, 1:1,000, anti-osterix (cat. no. ab94744, 1:1,000); mouse anti- HO-1 antibody (ab13248, 1:1,000), NQO1 antibody (ab34173, 1:1,000), Nrf2 antibody (ab137550, 1:1,000) and anti-GAPDH (ab9485, 1:1,000) overnight at 4°C, all purchased from Abcam (Cambridge, UK). The membranes were washed with TBST, and then incubated with horseradish peroxidase-conjugated secondary antibodies goat anti-rabbit (cat. no. ab205718; 1:2,000; Abcam) and goat anti-mouse (cat. no. ab205719; 1:5,000; Abcam) at 4°C for 1 h. The blots were visualized using enhanced chemiluminescence (ECL; Thermo Fisher Scientific, Inc.). An ECL system (Amersham; GE Healthcare, Chicago, IL, USA) was used to detect the bands. Quantity one software version 4.6.2 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used for densitometry analysis.

Statistical analysis. GraphPad Prism version 6.0 software (GraphPad Software, Inc., La Jolla, CA, USA) was used for conducting statistical analysis. Data are presented as the mean ± standard deviation. Statistical significance was analyzed using one-way analysis of variance, followed by Turkey’s multiple comparison test. P<0.05 was considered to indicate a statistically significant difference.

Results

Morphological observation of MC-3T3-E1 osteoblasts. After MC-3T3-E1 cells were inoculated and cultured for 24 h, the growth of adherent cells was observed using an inverted microscope (Fig. 1A). The cells showed a fibroblast-like appearance. To be more specific, the cells appeared to be irregular fusiform, triangular, or polygonal, and no fusion between cells was identified. As the duration of the culture time prolonged, cell bodies grew larger and the cell morphology was stretched. It appeared fiber bundles, triangles and polygons with more protuberances. Some elongated protuberances were often found to link cells with distant protuberant cells and to increase cell-to-cell contact. Meanwhile, the number of cells was found to increase, and cells were mostly spindle-shaped or cubic.

Protective effect of geniposide on CdCl₂-injured MC-3T3-E1 cells. The cytotoxic effects of different CdCl₂ concentrations (0-20 µM) at different time points (3, 6, 12 and 24 h) in MC-3T3-E1 cells were determined using CCK-8 assay. The results showed that CdCl₂ decreased MC-3T3-E1 cell viability in a dose- and time-dependent manner (20 µM, 3 h; P<0.05; 20 µM, 24 h, P<0.01; Fig. 1B). Based on this findings, 20 µM of CdCl₂ was employed in all subsequent experiments. Moreover, the cytotoxic effects of geniposide were also detected, and that geniposide had no cytotoxic effects at a concentration of 100-400 µg/ml (Fig. 1C). As showed in Fig. 1D, geniposide was able to ameliorate the CdCl₂ injury in cells and increase viability in a dose-dependent manner, and treatment using 400 µg/ml geniposide significantly increased cell viability (P<0.05).

Geniposide decreases the apoptosis induced by CdCl₂ in MC-3T3-E1 cells. As showed in Fig. 2A, the effect of geniposide on CdCl₂-induced apoptosis was investigated using flow cytometric analysis. We found that the apoptosis induced by CdCl₂ was significantly decreased in a concentration-dependent manner after being pretreated with geniposide (100 and 200 µg/ml: P<0.05, 400 µg/ml: P<0.01).

Geniposide decreases the ROS level in CdCl₂-injured MC-3T3-E1 cells. As showed in Fig. 2B, CdCl₂ exposure increased the ROS generation in MC-3T3-E1 cells (P<0.01). However, pretreatment of MC-3T3-E1 cells with geniposide significantly decreased the generation of ROS in a dose-dependent manner (P<0.01).

Geniposide affects MDA, LDH and antioxidant enzyme SOD activities in CdCl₂-injured MC-3T3-E1 cells. As showed in Fig. 3, the effects of geniposide on CdCl₂-induced oxidative stress-related factors were assessed using ELISA assay. We found that the level of MDA was not significantly increased by exposure of the cells to CdCl₂, and that pretreatments at different concentrations of geniposide also showed no significant effect on the level of MDA (P>0.05, Fig. 3A). However, LDH was significantly increased following exposure of the cells with CdCl₂. By contrast, a medium concentration of geniposide pretreatment significantly decreased the level of LDH, compared to the cells incubated with CdCl₂ (P<0.05, Fig. 3B). Our results also showed that antioxidant key enzyme SOD was decreased following CdCl₂ exposure, but SOD was significantly higher following pretreatment with a high concentration of geniposide (P<0.05, Fig. 3C).

Geniposide regulates the expression of Bax, Bcl-2 and survivin at the mRNA and protein levels of CdCl₂-injured MC-3T3-E1 cells. We determined the expression levels of Bax, Bcl-2 and survivin in MC-3T3-E1 cells using both western blotting and qPCR analyses. As shown in
Fig. 3d-G, compared with levels in cells exposed to \( \text{CdCl}_2 \), pretreatment with geniposide increased the expression of Bcl-2 and survivin both at mRNA and protein levels in a concentration-dependent manner (survivin, 200 \( \mu \text{g/ml} \) \( P<0.05 \); 400 \( \mu \text{g/ml} \) \( P<0.01 \)) and reduced the expression of Bax at the mRNA and protein levels (400 \( \mu \text{g/ml} \) \( P<0.01 \)). Both western blot and qPCR analysis showed that medium and high concentrations of geniposide could inhibit Bax, and increase Bcl-2 and survivin. These results showed that geniposide strongly antagonized the apoptotic process of \( \text{CdCl}_2 \)-induced MC-3T3-E1 cells.

Geniposide regulates the expression of RANKL, OPG and osterix at both the mRNA and protein levels in \( \text{CdCl}_2 \)-injured MC-3T3-E1 cells. In order to investigate whether geniposide could reverse the inhibition of \( \text{CdCl}_2 \) on osteoblast formation, we assessed the expression of osteoblast-related factors, RANKL, OPG and osterix, by carrying out western blot and qPCR analyses in MC-3T3-E1 cells. The results showed that exposure to \( \text{CdCl}_2 \) significantly inhibited osteoblast formation by increasing the expression of OPG and by decreasing the expression of RANKL and osterix both at the mRNA and protein levels. Medium concentration of geniposide significantly reversed the inhibition mediated by \( \text{CdCl}_2 \) on osteoblast formation through upregulating the expression of RANKL and osterix (\( P<0.01 \)) and downregulating the expression of OPG (\( P<0.05 \)). The protein levels (Fig. 4A-C) were consistent with the expression of mRNA (Fig. 4D).
Figure 2. Effects of different concentrations of geniposide on CdCl₂ (Cd)-induced apoptosis and reactive oxygen species (ROS) level in MC-3T3-E1 cells analyzed by flow cytometry. Cells were pretreated with geniposide [100 (low), 200 (medium) and 400 µg/ml (high)] for 24 h, followed by exposure to CdCl₂ (20 µM) for 3 h. (A) The apoptotic rate by flow cytometry. (B) ROS levels were analyzed using flow cytometry. Each point represents the mean ± standard deviation from three independent experiments. ▲P<0.05 and ▲▲P<0.01, compared with the control; *P<0.05 and **P<0.01, compared with CdCl₂ alone.
Geniposide regulates the downstream target genes of Nrf2 at both the mRNA and protein levels in CdCl₂-injured MC-3T3-E1 cells. In order to understand the mechanism of geniposide in Cd-induced osteoblast injury, the Nrf2 signaling pathway was evaluated in MC-3T3-E1 cells. As shown in Fig. 5, both qPCR and western blot analysis identified an increase in Nrf2, HO-1 and NQO1 expression in a dose-dependent manner following pretreatment with geniposide in the CdCl₂-injured MC-3T3-E1 cells. We found that a low concentration of geniposide significantly increased the mRNA expression of Nrf2 in comparison to that in cells exposed to CdCl₂ (P<0.05, Fig. 5A). However, both the increase of HO-1 and NQO1 mRNA expression required treatment with a medium concentration of geniposide (P<0.05, Fig. 5B and C). Western blot analyses also showed that a low concentration of geniposide increased the protein expression of Nrf2, HO-1 and NQO1 compared to that in cells exposed only to CdCl₂ (P<0.01, Fig. 5D).

Discussion

In the present study, osteoblast MC-3T3-E1 cells were pretreated with three different concentrations (100, 200 and 400 µg/ml) of geniposide for 24 h, and exposed to 20 µM CdCl₂ for additional 3 h. Furthermore, qPCR and western blot analysis showed that geniposide at a high concentration was able to significantly enhance the cell viability, while a low
Figure 4. Effects of different concentrations of geniposide on CdCl₂ (Cd)-induced mRNA and protein levels of osteoblast-related factors RANKL, OPG and osterix. Cells were pretreated with geniposide [100 (low), 200 (medium), 400 µg/ml (high)] for 24 h, followed by exposure to CdCl₂ (20 µM) for 3 h. (A-C) qPCR was used to determine the mRNA expression of RANKL, OPG and osterix. (D) Western blotting results and relative units of protein levels. Expression of each protein in control or geniposide-pretreated MC-3T3-E1 cells following normalization with a loading control GAPDH. Data are shown as the mean ± standard deviation from three independent experiments. ▲▲P<0.01, compared with the control; *P<0.05 and **P<0.01, compared with CdCl₂ alone. RANKL, receptor activator of NF-κB ligand.

Figure 5. Effects of different concentrations of geniposide on CdCl₂ (Cd)-induced mRNA and protein levels of Nrf2, HO-1 and NQO1. Cells were pretreated with geniposide [100 (low), 200 (medium), 400 µg/ml (high)] for 24 h, followed by exposure to CdCl₂ (20 µM) for 3 h. (A-C) qPCR was used to determine the mRNA expression of Nrf2, HO-1 and NQO1. (D) Western blotting results and relative units of protein levels. Expression of each protein in control or geniposide pretreated MC-3T3-E1 cells following normalization with a loading control GAPDH. Data are expressed as the mean ± standard deviation from three independent experiments. *P<0.05 and **P<0.01, compared with the control; ▲P<0.05 and ▲▲P<0.01, compared with CdCl₂ alone. Nrf2, nuclear factor erythroid 2-related factor; HO-1, heme oxygenase-1; NQO1, NAD(P)H quinone dehydrogenase 1.
concentration of geniposide could antagonize apoptosis by downregulating Bax and upregulating both Bcl-2 and survivin.

Furthermore, we found that geniposide could reverse the injury of CdCl₂ on osteoblast formation, which is consistent with another study in which geniposide promoted osteoblast formation (33). As previously reported, the RANKL/RANK/OPG system is an important signal transduction pathway in the process of bone metabolism. The receptor activator of RANKL with its cognate receptor (RANK) promotes differentiation and bone resorption activity of osteoclasts. OPG can also combine RANK, disrupting the balance of bone metabolism (17,41,42). It has been suggested that cadmium can accumulate in human osteoblast-like MG-63 cells and affect their viability, and that high concentrations of cadmium could inhibit bone formation via the OPG/RANKL pathway (17,43). However, a limited number of studies have focused on geniposide in relation to RANKL and OPG in osteoblast cells. In the present study, we demonstrated that low-dose geniposide obviously increased expression of RANKL, and that a medium-dose could decrease expression of OPG. Osterix is a novel transcription factor in the differentiation of osteoblasts, and it is specifically expressed in all developing bones (44). Geniposide promotes osteogenic activity of osteoblasts by increasing the expression of osterix in a dose-dependent manner. It was indicated that geniposide promoted the balance of bone metabolism.

Occupational cadmium exposure and domestic cadmium pollution seriously affect the health of individuals worldwide, causing neuronal damage, cardiovascular effects, reproductive toxicity and osteoblast injury (4,7,45,46). A large amount of evidence has confirmed that reducing internal oxidative stress and increasing endogenous antioxidant proteins are vital in avoiding cell injury (26,34,39,47). Pan et al (48) highlighted the importance of oxidative stress in cadmium exposure disorder, and many compounds produce protective effects against cadmium-induced oxidative injury, for example, quercetin, catechin and nobiletin (49-51). Geniposide had been reported to protect against cadmium-induced toxic oxidative stress in rat kidney tissue (25). Thus, we concluded that geniposide may prevent cadmium-induced injury.

Reactive oxygen species (ROS) are generally produced in the mitochondria. Excessive exogenous oxidants and certain extreme environments including heavy metal, chemotherapeutic drugs, sodium fluoride lead to the overproduction of ROS (52-54). Over-generated ROS damage proteins, lipids and DNA, ultimately causing cell death or apoptosis. CdCl₂ exposure was found to significantly increase ROS generation (55,56). Geniposide was found to noticeably decrease ROS levels, to downregulate LDH and to upregulate antioxidant enzyme SOD. In order to understand the protective mechanism of geniposide against oxidative stress injury, we detected the downstream target genes of Nrf2, HO-1 and NQO1. Nrf2, a basic leucine-zipper transcription factor, plays an important role in preventing the development of oxidative stress and is also one of the essential regulators of antioxidative stress genes. The role of Nrf2 has been confirmed using Nrf2 knock-out mice in vivo, and it binds to antioxidant response element (ARE) sites in the promoter of cytoprotective phase II genes to regulate their expression (57-61). Our study showed that geniposide not only completely increased the mRNA and protein expression of Nrf2, but also increased antioxidant protein HO-1 and phase II detoxifying enzyme NQO1. Thus, we inferred that the induction of Nrf2 could promote the downstream genes HO-1 and NQO1 so as to attenuate the oxidative stress reaction. Taken together, our study indicated that geniposide could induce Nrf2, suggesting that the Nrf2 pathway may take part in the progressive effects of geniposide on antioxidative stress.

In conclusion, our finding suggests that geniposide could antagonize oxidative stress caused by CdCl₂. Activation of Nrf2, HO-1 and NQO1 may be associated with the effect of geniposide on MC-3T3-E1 cells. Our study identifies a potential agent for the treatment of cadmium-induced osteoblast injury.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions
TH and HS made substantial contributions to the conception and design of the study. JZ, YZ, HL and YH performed data acquisition, data analysis and interpretation. TH and HS drafted the article, critically revised its intellectual content. All authors read and approved the final version of the manuscript. TH, HS, ZL and HL agreed to be accountable for all aspects of the work and ensuring that questions related to the accuracy or integrity of the work were appropriately investigated and resolved.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Sato K, Iwamasa T, Tsuru T and Takeuchi T: An ultrastructural study of chronic cadmium chloride-induced neuropathy. Acta Neuropathol 41: 185-190, 1978.
2. Sakata S, Iwami K, Enoki Y, Kohzuki H, Shimizu S, Matsuda M and Moriyama T: Effects of cadmium on iron and in vivo erythropoiesis: Erythroid progenitor cells (CFU-E), iron and erythropoietin in cadmium-induced iron deficiency anemia. Exp Hematol 16: 581-587, 1988.
3. Blakley BR: Humoral immunity in aged mice exposed to cadmium. Can J Vet Res 52: 291-292, 1988.

4. Saygi S, Deniz G, Kutsal O and Vural N: Chronic effects of cadmium on kidney, liver, testis and fertility of male rats. Biol Trace Elem Res 200:214, 1991.

5. Sakamoto M, Itai T and Murata K: Effects of prenatal methylmercury exposure: From minamata disease to environmental health studies. Nihon Eiseigaku Zasshi 72: 140-148, 2017 (In Japanese).

6. Morikawa Y, Kawanabe H, Tabata M, Nishijo M, Senma M, Kitagawa Y, Kawano S, Teranishi H and Kido T: Study of an outbreak of itai-itai disease. Nihon Eiseigaku Zasshi 46: 1057-1062, 1992 (In Japanese).

7. Kong YY, Yoshida H, Sarosi i, Tan Hl, Timms e, capparelli c, et al: Cadmium on kidney, liver, testis and fertility of male rats. Biol Pharm Bull 29: 174-176, 2006.

8. Bhattacharyya MH, Whelton BD, Stern PH and Peterson DP: Cadmium accelerates bone loss in ovariectomized mice and fetal rat limb bones in culture. Proc Natl Acad Sci USA 85: 8761-8765, 1988.

9. WHO: Environmental Health Criteria. Cadmium-Environmental Aspects 135:134-136, 1992.

10. Martineau C, Abed E, Medina G, Jomphe et al: Involvement of transient receptor potential melastatin-related 7 (TRPM7) channels in cadmium uptake and cytotoxicity in MC3T3-E1 osteoblasts. Toxicol Lett 197: 585-593, 2010.

11. Kawamura J, Yoshida O, Nishino K and Itokawa Y: Disturbances in kidney functions and calcium and phosphate metabolism in cadmium-poisoned rats. Nephron 20: 101-110, 1978.

12. Shinichi S and Kiyoshi N: Effects of vitamin D on calcium and bone metabolism. Clin Calcium 13: 863-868, 2003 (In Japanese).

13. Wang C and Bhattacharyya M: Effect of cadmium on bone calcium and 45Ca in nonpregnant mice on a calcium-deficient diet: Evidence of direct effect of cadmium on bone. Toxicol Appl Pharmacol 120: 228-239, 1993.

14. Brama M, Politi L, Santini P, Migliaccio S and Scandurra R: Cadmium-induced apoptosis and necrosis in human osteoblasts: Role of caspases and mitogen-activated protein kinases pathways. J Endocrinol Invest 35: 198-208, 2012.

15. Wallin M, Barregard L, Sallsten G, Lundh T, Karlsson MK, Lorentzon M, Ohlsson C and Mellström D: Low-level cadmium exposure is associated with decreased bone mineral density and increased risk of incident fractures in elderly men: The MrOS Sweden study. J Bone Miner Res 31: 732-741, 2016.

16. Wilson AK, Cerny EA, Smith BD, Wagh A and Bhattacharyya MH: Effects of cadmium on osteocalcification and formation in vitro. Toxicol Appl Pharmacol 140: 451-460, 1996.

17. Chen X, Zhu G, Gu S, Jin T and Shao C: Effects of cadmium on osteoblasts in vitro. Environ Toxicol Pharmacol 28: 232-236, 2009.

18. Coonse KG, Coonts AJ, Morrison EV and Heggland SJ: Cadmium-induced oxidative cellular damage in human fetal lung fibroblasts (MRC-5 cells). Environ Health Perspect 105: 712-716, 1997.

19. Thompson J and Bannigan J: Cadmium: Toxic effects on the reproductive system and the embryo. Reprod Toxicol 20: 304-315, 2004.

20. Joseph P: Mechanisms of cadmium carcinogenesis. Toxicol Appl Pharmacol 238: 272-279, 2009.

21. Bertin G and Averbeck D: Cadmium: Cellular effects, modification of biomolecules, modulation of DNA repair and genotoxic consequences (a review). Biochimie 88: 1549-1559, 2006.

22. López E, Arce C, Oset-Gasque MJ, Cañadas S and González MP: Cadmium induces reactive oxygen species generation and lipid peroxidation in cortical neurons in culture. Free Radic Biol Med 40: 940-951, 2006.

23. Koo HJ, Lim KH, Jung HJ and Park EH: Anti-inflammatory effects of Gardenia jasminoides extract, geniposide and genipin. J Ethnopharmacol 103: 496-500, 2006.

24. Liu E, Han L, Wang J, He W, Shang H, Gao X and Wang T: Eucommia ulmoides bark protects against renal injury in cadmium-challenged rats. J Med Food 15: 307-314, 2012.

25. Yin F, Liu J, Zheng X, Guo L and Xiao H: Geniposide induces the expression of H2O2 and NO via eNOS- and NOS signaling to enhance the antioxidant capacity in primary hippocampal neurons. Biol Pharm Bull 33: 1841-1846, 2010.

26. Wang SW, Lai CY and Wang CJ: Inhibitory effect of geniposide on aflatoxin B1-induced DNA repair synthesis in primary cultured rat hepatocytes. Cancer Lett 65: 133-137, 1992.

27. Koo HJ, Lee S, Shin KH, Kim BC, Lim CJ and Park EH: Geniposide, an anti-allergic and anti-inflammatory flavone from the fruits of Gardenia jasminoides. Planta Med 70: 467-469, 2004.

28. Wang J, Hou J, Zhang P, Li D, Zhang C and Liu J: Geniposide reduces inflammatory responses of oxygen-glucose deprived rat microglial cells via inhibition of the TLR4 signaling pathway. Neurochem Res 37: 2235-2248, 2012.

29. Wang J, Li D, Hou J and Lei H: Protective effects of geniposide and ginsenoside Rg1 combination treatment on rats following cerebral ischemia are mediated via microglial microRNA-155-5p inhibition. Mol Med Rep 17: 3186-3193, 2018.

30. Chang CH, Wu JB, Yang JS, Lai YJ, Su CH, Lee CC and Hsu YM: The suppressive effects of geniposide and genipin on helicobacter pylori infections in vitro and in vivo. J Food Sci 82: 2021-2027, 2012.

31. Ha H, Ho J, Shin S, Kim H, Koo S, Kim IH and Kim C: Effects of eucommiae cortex on osteoblast-like cell proliferation and osteoblast inhibition. Arch Pharm Res 26: 929-556, 2003.

32. Lin J, Fan YJ, Mehl C, Zhu JJ, Chen H, Jin LY, Xu JH and Wang HM: Eucommia ulmifolia Olív. antagonizes H2O2-induced rat osteoblastic MC3T3-E1 apoptosis by inhibiting expressions of caspases 3, 6, 7 and 9. J Zhejiang Univ Sci B 12: 47-54, 2011.

33. Liu Y, Jin F, Zheng X, Jing J and Hu Y: Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Int 51: 361-369, 2007.

34. Chen Y, Zhang H, Li YX, Cai L, Huang J, Zhao C, Jia L, Zhang G, Lu B, Liu S, et al: Synergistic neuroprotective effects of Geniposide and ursoodeoxycholic acid in hypoxia-reoxygenation injury in SH-SY5Y cells. Exp Ther Med 15: 320-326, 2018.

35. Hu KH, Li WX, Sun MY, Zhang SB, Fan CX, Wu Q, Zhu W and Xu X: Cadmium induced apoptosis in MG63 cells by increasing ROS, activation of p38 MAPK and inhibition of ERK 1/2 Pathways. Cell Physiol Biochem 36: 642-654, 2015.

36. Pathak N and Khandelwal S: Influence of cadmium on murine macrophages: Potential involvement of apoptosis and oxidative stress. Toxicol Lett 165: 121-132, 2006.

37. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(–Delta Delta Ct) method. Methods 25: 402-408, 2001.

38. Theoleyre S, Witrant Y, Tat SK, Demurger H, Redini F and Heymann D: The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15: 475-475, 2004.

39. Roodman GD: Treatment strategies for bone disease. Bone Marrow Transplant 40: 1139-1146, 2007.

40. Valois AA and Webster WS: The chordoid plexus as a target site for cadmium toxicity following chronic exposure in the adult mouse: An ultrastructural study. Toxicology 55: 193-205, 1989.

41. Jamall iS, Naik M, Sprowls JJ and Trombetta LD: A comparison of the effects of dietary cadmium on heart and kidney antioxidant enzymes: evidence for the greater vulnerability of the heart to cadmium toxicity. J Appl Toxicol 9: 339-345, 1989.

42. Liu E, Han L, Wang J, He W, Weng J, Wang H, Gao X and Wang T: Eucommia ulmoides bark protects against renal injury in cadmium-challenged rats. J Med Food 15: 307-314, 2012.
48. Pan YX, Luo Z, Zhuo MQ, Wei CC, Chen GH and Song YF: Oxidative stress and mitochondrial dysfunction mediated Cd-induced hepatic lipid accumulation in zebrafish Danio rerio. Aquat Toxicol 199: 12-20, 2018.

49. Mao T, Han C, Wei B, Zhao L, Zhang Q, Deng R, Liu J, Luo Y and Zhang Y: Protective effects of quercetin against cadmium chloride-induced oxidative injury in goat sperm and zygotes. Biol Trace Elem Res 185: 344-355, 2018.

50. Wongmekiat O, Peerapanyasut W and Kobroob A: Catechin supplementation prevents kidney damage in rats repeatedly exposed to cadmium through mitochondrial protection. Naunyn Schmiedebergs Arch Pharmacol 391: 385-394, 2018.

51. Qu Y, Liu Y, Chen L, Zhu Y, Xiao X, Wang D and Zhu Y: Nobiletin prevents cadmium-induced neuronal apoptosis by inhibiting reactive oxygen species and modulating JNK/ERK1/2 and Akt/mTOR networks in rats. Neurrol Res 40: 211-220, 2018.

52. Kováčik J, Dresler S, Peterková V and Babula P: Metal-induced oxidative stress in terrestrial macrolichens. Chemosphere 203: 402-409, 2018.

53. Varricchi G, Ameri P, Cadeddu C, Ghigo A, Madonna R, Marone G, Mercurio V, Monte I, Novo G, Parrella P, et al: Antineoplastic drug-induced cardiotoxicity: A redox perspective. Front Physiol 9: 167, 2018.

54. Kim J, Kwon WS, Rahman MS, Lee JS, Yoon SJ, Park YJ, You YA and Pang MG: Effect of sodium fluoride on male mouse fertility. Andrology 3: 544-551, 2015.

55. Chatterjee S, Kundu S, Sengupta S and Bhattacharyya A: Divergence to apoptosis from ROS induced cell cycle arrest: Effect of cadmium. Mutat Res 663: 22-31, 2009.

56. Wang SH, Shih YL, Kuo TC, Ko WC and Shih CM: Cadmium toxicity toward autophagy through ROS-activated GSK-3beta in mesangial cells. Toxicol Sci 108: 124-131, 2009.

57. Sporn MB and Liby KT: NRF2 and cancer: The good, the bad and the importance of context. Nat Rev Cancer 12: 564-571, 2012.

58. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S and Yamamoto M: Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 275: 16023-16029, 2000.

59. Lee IT, Wang SW, Lee CW, Chang CC, Lin CC, Luo SF and Yang CM: Lipoteichoic acid induces HO-1 expression via the TLR2/MyD88/c-Src/NADPH oxidase pathway and Nrf2 in human tracheal smooth muscle cells. J Immunol 181: 5098-5110, 2008.

60. Nguyen T, Sherratt PJ and Pickett CB: Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 43: 233-260, 2003.

61. Khor TO, Huang MT, Prawan A, Liu Y, Hao X, Yu S, Cheung WK, Chan JY, Reddy BS, Yang CS and Kong AN: Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev Res (Phila) 1: 187-191, 2008.